What Drugs Should Not Be Taken With Olmesartan?

Olmesartan belongs to a class of blood pressure medications called angiotensin receptor blockers (ARBs), and several common drugs can cause serious problems when combined with it. The most frequently flagged interactions involve anti-inflammatory painkillers, other blood-pressure-lowering drugs that work through the same hormonal pathway, lithium, potassium supplements, and certain cholesterol-lowering agents. Some of these combinations raise the risk of kidney damage or dangerously high potassium levels, while others simply prevent olmesartan from working properly.

Anti-Inflammatory Painkillers

Nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, are among the most widely used medications on the planet. Ibuprofen, naproxen, diclofenac, and celecoxib all fall into this category, and all of them can blunt the blood-pressure-lowering effect of olmesartan. The mechanism is straightforward: NSAIDs reduce blood flow through the kidneys by constricting certain blood vessels, while olmesartan relies partly on keeping those same vessels relaxed. When both are present, the kidney gets squeezed from two directions.

The concern goes beyond just a less effective blood pressure pill. In people whose kidneys are already under stress, adding an NSAID on top of olmesartan (especially if a diuretic like hydrochlorothiazide is also in the mix) can trigger acute kidney injury. A published case report documented exactly this scenario: the combination of hydrochlorothiazide, ibuprofen, and olmesartan led to acute tubular injury requiring medical intervention.¹ This triple combination is sometimes called the “triple whammy” in pharmacy circles because it hits kidney perfusion from three angles at once.

An occasional ibuprofen for a headache is unlikely to land you in the hospital, but regular NSAID use while taking olmesartan is a different story. If you need ongoing pain relief, acetaminophen (Tylenol) is generally considered safer with ARBs since it does not share the kidney-constricting properties. For chronic inflammatory conditions, talk to your prescriber about alternatives that do not interact with your blood pressure regimen.

Other Drugs That Act on the Same Blood Pressure Pathway

Olmesartan works by blocking the action of a hormone called angiotensin II. Two other drug classes target the same system: ACE inhibitors (like lisinopril, enalapril, and ramipril) and direct renin inhibitors (like aliskiren). Combining olmesartan with either of these is called “dual RAAS blockade,” and it has been tested extensively in clinical trials. The results were not encouraging.

In theory, blocking the system at two points should produce better blood pressure control or more kidney protection. In practice, the combination significantly increases the risk of hyperkalemia (dangerously high potassium), low blood pressure, and kidney failure. A randomized study of patients with moderate chronic kidney disease found that both olmesartan and enalapril independently caused a rapid jump in potassium levels within one week of starting treatment: about a 10.5% increase with olmesartan and a 10.7% increase with enalapril.² Roughly four in ten patients in each group developed hyperkalemia. Stacking both drug types together would compound that risk further.

The combination of any ARB with aliskiren is now specifically contraindicated in people with diabetes or moderate-to-severe kidney disease, and most clinical guidelines discourage it in anyone. If your current regimen involves both an ARB and an ACE inhibitor, that warrants a conversation with your doctor, because the evidence strongly favors using one or the other rather than both.

Potassium Supplements and Potassium-Sparing Diuretics

Because olmesartan already raises potassium levels on its own, anything else that pushes potassium higher is a potential problem. Potassium supplements are the obvious one, but several prescription medications also retain potassium as a side effect. Spironolactone, eplerenone, amiloride, and triamterene are all “potassium-sparing” diuretics that can push levels into dangerous territory when paired with an ARB.

The same randomized study mentioned above showed that olmesartan alone raised serum potassium from a baseline of about 4.35 to 4.59 mmol/L within a single week.² That already approaches the upper end of the normal range, and adding a potassium-sparing diuretic or a daily potassium supplement can tip the balance. High potassium is not something you feel coming; it can cause dangerous heart rhythm changes with little warning. If you are on olmesartan and have been told to use a potassium supplement or salt substitute (many of which contain potassium chloride), your doctor should be monitoring your blood levels regularly.

Trimethoprim, an antibiotic commonly prescribed for urinary tract infections, also raises potassium and deserves a mention here. It is easy to overlook because it is a short-course antibiotic, not a daily medication, but the interaction is real and has caused emergency-room visits in people already on ARBs.

Lithium

Lithium, used to treat bipolar disorder, has a narrow therapeutic window, meaning the difference between an effective dose and a toxic one is small. ARBs, including olmesartan, can reduce the kidney’s ability to clear lithium from the body, causing blood levels to climb into the toxic range. A review of the interaction between lithium and antihypertensive medications confirmed that ARBs, ACE inhibitors, thiazide diuretics, and NSAIDs can all decrease renal clearance of lithium and lead to elevated serum levels and toxicity.³

Lithium toxicity can cause tremors, confusion, vomiting, seizures, and in severe cases kidney failure or death. If you take lithium and need a blood pressure medication, it does not automatically mean olmesartan is off the table, but your psychiatrist and prescribing doctor need to coordinate closely. Lithium levels should be checked more frequently after starting, stopping, or changing the dose of any ARB, and the same goes for adding or removing a diuretic from the regimen.

Bile Acid Sequestrants and Timing-Sensitive Interactions

Colesevelam is a cholesterol-lowering drug that works by binding bile acids in the gut. The trouble is that it also binds olmesartan, preventing it from being absorbed into the bloodstream. A pharmacokinetic study found that taking colesevelam at the same time as olmesartan reduced olmesartan exposure by about 39%.⁴ That is a substantial hit; nearly two-fifths of the drug never reaches your system.

The good news is that this interaction is solvable without switching medications. The same study showed that spacing the two drugs about four hours apart largely eliminated the absorption problem. If you take both colesevelam and olmesartan, the standard advice is to take olmesartan at least four hours before the colesevelam dose. Other bile acid sequestrants like cholestyramine and colestipol likely behave similarly, since their binding action in the gut is the same.

Olmesartan During Pregnancy

This is not a drug interaction in the traditional sense, but it is arguably the most critical safety warning associated with olmesartan. All ARBs, including olmesartan, are contraindicated during pregnancy because they can cause severe harm to the developing fetus. The damage stems from reduced blood flow through fetal blood vessels. Reported consequences include kidney failure in the newborn, underdeveloped skull bones, lung underdevelopment, and fetal death.⁵

Exposure during the second and third trimesters carries the highest risk. A review of published cases found that nearly all pregnant women treated with ARBs during those trimesters gave birth to babies with fetal abnormalities or stillbirths.⁵ First-trimester exposure also carries measurable risk, with some data suggesting around 6% of exposed pregnancies show major abnormalities. If you are taking olmesartan and become pregnant or plan to become pregnant, the medication should be stopped as soon as possible and replaced with a pregnancy-safe alternative like labetalol or nifedipine.

Immunosuppressants and Kidney Stress

Tacrolimus and cyclosporine are immunosuppressant drugs used after organ transplants and in certain autoimmune conditions. Both are known to be hard on the kidneys, and combining them with olmesartan creates a complicated picture. Animal research has shown that olmesartan can actually reduce some markers of kidney damage caused by tacrolimus: in a rat model, adding olmesartan significantly lowered creatinine and BUN levels that had been elevated by tacrolimus treatment, and also reduced oxidative stress in kidney tissue.⁶

That sounds promising, but the clinical reality is more nuanced. Both drugs affect the kidneys and potassium handling, so combining them in a real patient requires careful monitoring of kidney function and electrolytes. Tacrolimus levels can also be influenced by changes in kidney blood flow, which olmesartan alters. Transplant recipients are typically managed by specialists who already track these levels closely, but if you are on tacrolimus for a non-transplant condition and your primary care doctor prescribes olmesartan, make sure both providers are in the loop.

Olmesartan’s Unique Gastrointestinal Side Effect

While not a drug interaction, olmesartan has a distinctive adverse effect that no other ARB on the market shares at the same frequency, and understanding it matters for anyone on the drug. Some patients develop a condition called sprue-like enteropathy: severe, chronic diarrhea with weight loss, nausea, and damage to the lining of the small intestine that mimics celiac disease. The difference is that celiac blood markers come back negative, and a gluten-free diet does not help.⁷

Case reports illustrate how debilitating this can be. One documented case involved a 69-year-old woman who experienced persistent watery diarrhea with up to 20 bowel movements per day for a full year, losing 10 kg during that time. Capsule endoscopy revealed villous atrophy throughout her small bowel. After olmesartan was stopped, her diarrhea improved and follow-up endoscopy confirmed the intestinal damage was healing.⁸ Another case showed complete clinical improvement after stopping olmesartan, with histological resolution confirmed on repeat endoscopy.⁹

This matters in the context of drug interactions because the enteropathy can be worsened or confused by other gastrointestinal medications. If you are on olmesartan and develop unexplained chronic diarrhea, the drug itself should be considered as a cause before adding anti-diarrheal medications or undergoing invasive diagnostic procedures. The fix is simply switching to a different ARB or another class of blood pressure medication entirely.

Polypharmacy and Fall Risk in Older Adults

Older adults are the population most likely to be on olmesartan, and they are also the population most likely to be taking a long list of other medications. This creates its own category of risk that goes beyond any single drug interaction. Research into polypharmacy and falls found that taking multiple medications was associated with increased fall risk, but only when the regimen included at least one drug already known to raise fall risk, such as a central nervous system depressant or a diuretic.¹⁰

Olmesartan can lower blood pressure enough to cause dizziness when standing, particularly in the first few weeks of treatment or after a dose increase. If you are also taking a sedative, an opioid pain medication, a sleep aid, or a thiazide diuretic, the combined blood-pressure-lowering and sedative effects stack up. For older adults, a fall can be far more consequential than for a younger person, meaning the risk-benefit calculation of every added medication deserves scrutiny. Periodic medication reviews with a pharmacist or geriatrician can identify combinations that increase fall risk without providing proportional benefit.

Drugs That Are Generally Safe With Olmesartan

It is worth briefly noting what is generally not a problem, because the interaction lists can make it feel like nothing is safe. Olmesartan is routinely combined with calcium channel blockers (like amlodipine), thiazide diuretics (like hydrochlorothiazide, though this adds potassium and kidney monitoring requirements), and beta-blockers without major pharmacokinetic interactions. In fact, fixed-dose combination pills pairing olmesartan with amlodipine or hydrochlorothiazide are widely prescribed.

There has also been some concern about combining blood pressure drugs with erectile dysfunction medications like sildenafil. Evidence from a review of sildenafil with various antihypertensive classes, including the drug families olmesartan belongs to, found that the blood pressure drop is additive rather than dangerously multiplied, and is unlikely to cause clinically significant problems in most people.¹¹ That said, if you are on multiple blood-pressure-lowering medications at once, or if you already experience dizziness from your regimen, the added drop from sildenafil could be enough to cause lightheadedness or fainting. Mention it to your prescriber so they can advise on timing and dose.

When to Be Extra Cautious

Some people face a higher baseline risk from olmesartan interactions than others. If you have chronic kidney disease, even mild, your kidneys are already less able to handle the potassium shifts and perfusion changes that olmesartan causes. Adding an NSAID, a potassium supplement, or another RAAS-acting drug on top is riskier for you than for someone with healthy kidneys. The randomized trial comparing olmesartan and enalapril in patients with moderate chronic kidney disease found that roughly 37 to 40% of participants developed hyperkalemia on either drug alone.² That is a high baseline rate without any interaction layered on top.

People who are dehydrated, on a low-sodium diet, or taking high doses of diuretics also face elevated risk, because olmesartan’s blood-pressure-lowering effect becomes exaggerated when fluid volume is low. Starting or restarting olmesartan after an illness involving vomiting or diarrhea, for instance, is a moment when kidney function and blood pressure deserve close attention. If you are managing multiple chronic conditions with several prescribers, make sure every doctor and pharmacist has your complete medication list. The interactions described in this article are well-characterized and avoidable with proper coordination.